Anti-CD22-NMS249
Product Specifications
CAS Number
9007-83-4
UNSPSC Description
Anti-CD22-NMS249 is a CD22-targeting antibody-drug conjugate (ADC). Anti-CD22-NMS249 is composed of a humanized anti-CD22 antibody Pinatuzumab (HY-P99230), a cleavable linker (Mc-VC-PAB), and a DNA topoisomerase II inhibitor payload PNU-159682 (HY-16700). Anti-CD22-NMS249 can be used for research in non-Hodgkin lymphoma (NHL)[1].
Target Antigen
Antibody-Drug Conjugates (ADCs); CD22
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related;Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/anti-cd22-nms249.html
Smiles
[Anti-CD22-NMS249]
References & Citations
[1]Shang-Fan Yu, et al. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs. Clin Cancer Res. 2015 Jul 15;21(14):3298-306.
Shipping Conditions
Room temperature
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC682869-100 1x 100 µL
TAG-72 / CA72.4 (Tumor-Associated Glycoprotein) (CA72/2869R), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details